Chandan Healthcare Shares Surge 3% after ₹104.13 Crore Fund Raise Approval and Jeena Sikho Lifecare Association

Lucknow, October 14, 2025: Chandan Healthcare Limited (NSE: CHANDAN) gained 3.14% in Tuesday’s trading session. This surge came as the board approved a ₹104.13 crore fund raise through a preferential issue of convertible warrants and declared a nationwide diagnostic association with Jeena Sikho Lifecare Limited.

Founded in 2003, Chandan Healthcare Limited is an integrated healthcare and diagnostics company based in North India and a part of the Chandan Group. The company provides end-to-end pathology, radiology, and pharmacy services with a strong presence in Uttar Pradesh, Uttarakhand, Rajasthan, and Bihar, and an ambition to expand in central and northern India as well.

Fund Raise Details

The preferential allotment includes fully convertible warrants of equity at ₹234 per warrant, aggregating 44.5 lakh warrants. 4.75 lakh warrants have been allotted to the promoter group and 39.75 lakh warrants to non-promoters, out of which 18 lakh warrants were allotted to strategic investor Jeena Sikho Lifecare Ltd. The move reflects strong investor confidence in the growth path of Chandan Healthcare.

Strategic Partnership with Jeena Sikho Lifecare

Chandan Healthcare will be the sole diagnostic partner of Jeena Sikho hospitals and clinics located in 23 states and over 100 cities under the partnership. The partnership unites pathology and radiology services for IPD and OPD patients with a vision to expand the reach for low-cost, technology-enabled diagnostics nationwide. Amar Singh, Managing Director and Promoter, averred that the fundraising and strategic partnership are milestones in Chandan’s expansion strategy to emerge as a leading integrated healthcare brand. A substantial portion of the proceeds will be invested in the opening of new diagnostic labs, an increase in infrastructure, and working capital requirements for growth.

Financial and Operational Overview

In FY25, Chandan Healthcare registered revenue of ₹230.12 crore, EBITDA of ₹43.38 crore, and net profit of ₹22.17 crore. The company operates with 40 diagnostic centers and over 360 collection centers located across North India, supported by 1,300 professionals and a few NABL and NABH-certified labs. The company caters to B2C and B2B segments, including hospitals, government orders, and retail pharmacy services. Expansion plans include new centers in Madhya Pradesh, Delhi, and Chhattisgarh.

Market Response

Chandan Healthcare shares closed at ₹311.90, up ₹9.50 after touching a fresh 52-week high of ₹317.50 at 1:47 p.m. IST. The company’s market cap was at ₹758 crore with an adjusted P/E multiple of 57.59, reflecting good investor sentiment.

REF: https://nsearchives.nseindia.com/corporate/CHANDAN_13102025143808_Press_Release.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations